WallStSmart

AbbVie Inc (ABBV)vsQT Imaging Holdings, Inc. Common Stock (QTI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 243491% more annual revenue ($64.39B vs $26.43M). ABBV leads profitability with a 9.8% profit margin vs -77.3%. ABBV earns a higher WallStSmart Score of 73/100 (B).

ABBV

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 8.5Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

QTI

Avoid

30

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 5/9Altman Z: -4.07
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-69.4%)

Margin of Safety

-69.4%

Fair Value

$151.82

Current Price

$261.74

$109.92 premium

UndervaluedFair: $151.82Overvalued

Intrinsic value data unavailable for QTI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$454.36B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
40.0%10/10

Strong operational efficiency at 40.0%

EPS GrowthGrowth
290.4%10/10

Earnings expanding 290.4% YoY

Debt/EquityHealth
-11.9310/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.528/10

Growing faster than its price suggests

QTI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
103.2%10/10

Revenue surging 103.2% year-over-year

Areas to Watch

ABBV2 concerns · Avg: 2.0/10
P/E RatioValuation
72.0x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

QTI4 concerns · Avg: 3.5/10
Price/BookValuation
16.5x4/10

Trading at 16.5x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$38.64M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.933/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.

Bull Case : QTI

The strongest argument for QTI centers on Revenue Growth. Revenue growth of 103.2% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.

Bear Case : QTI

The primary concerns for QTI are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 1.93 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABBV profiles as a value stock while QTI is a hypergrowth play — different risk/reward profiles.

ABBV carries more volatility with a beta of 0.28 — expect wider price swings.

QTI is growing revenue faster at 103.2% — sustainability is the question.

ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (73/100 vs 30/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

QT Imaging Holdings, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

QT Imaging Holdings, Inc. engages in the manufacturing, research, and development of automated breast imaging system for producing high-resolution transmission ultrasound images. The company is headquartered in Novato, California.

Want to dig deeper into these stocks?